Research guide
Best GLP-1 Peptides for Research
GLP-1 receptor agonists and related incretin-pathway compounds are among the most actively researched peptides in metabolic science. Three compounds represent the current state of the art: a single GLP-1 agonist, a dual GIP/GLP-1 agonist, and a triple GLP-1/GIP/glucagon agonist. Each engages a different combination of receptors, making them distinct tools for different research questions. This page compares all three. All products are supplied as lyophilised research compounds for in-vitro laboratory use only.
At a glance
Quick comparison of the compounds covered on this page.
1. Semaglutide
Mechanism and research context
Semaglutide is a selective GLP-1 receptor agonist, structurally modified for extended half-life through albumin binding. It is the most widely studied compound in the GLP-1 class and serves as the benchmark reference in incretin-pathway research. Its single-receptor selectivity makes it valuable for isolating GLP-1-specific effects in experimental designs.
Key research areas
Purity and supply
Supplied as a lyophilised research compound against a batch specification of at least 98% HPLC purity. Selected lots are independently tested by Janoshik Analytical, with each report published in the COA Vault and verifiable on Janoshik's own portal. CertaPeptides is a reseller -- we supply Semaglutide as provided by our supplier.
2. Tirzepatide
Mechanism and research context
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist that engages both incretin pathways simultaneously. Its twisting peptide is a central tool in research comparing single-agonist versus dual-agonist activity. Studies examine whether the addition of GIP receptor engagement produces differential effects compared to GLP-1 agonism alone.
Key research areas
Purity and supply
Supplied as a lyophilised research compound against a batch specification of at least 98% HPLC purity. Selected lots are independently tested by Janoshik Analytical, with each report published in the COA Vault and verifiable on Janoshik's own portal. CertaPeptides is a reseller -- we supply Tirzepatide as provided by our supplier.
3. Retatrutide
Mechanism and research context
Retatrutide (LY3437943) is a single-molecule triple receptor agonist that acts at GLP-1, GIP, and glucagon receptors simultaneously. It represents the newest generation of incretin-pathway tools, studied for whether engaging the glucagon receptor alongside the two incretin receptors produces distinct research outcomes compared to dual or single agonists.
Key research areas
Purity and supply
Supplied as a lyophilised research compound against a batch specification of at least 98% HPLC purity. Selected lots are independently tested by Janoshik Analytical, with each report published in the COA Vault and verifiable on Janoshik's own portal. CertaPeptides is a reseller -- we supply Retatrutide as provided by our supplier.
How to choose
For research requiring a GLP-1-only control, Semaglutide is the standard reference compound with the deepest published literature. Tirzepatide is the appropriate tool for studying dual GIP/GLP-1 interactions or comparing dual-agonist versus single-agonist activity. Retatrutide adds the glucagon receptor axis and is suited to research on triple-pathway engagement or comparative studies across the full agonist class. Many research protocols use all three together as a single-vs-dual-vs-triple comparison set.
Further reading
All products sold by CertaPeptides are intended for laboratory research use only and are not for human or animal consumption. CertaPeptides (CERTALAB S.R.L.) is a reseller, not a manufacturer -- we supply each compound as provided by our supplier and do not make any medical, therapeutic, or efficacy claims. The research areas described on this page reflect topics covered in the published scientific literature and do not constitute recommendations for any specific application.